[go: up one dir, main page]

MX2009012990A - Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica. - Google Patents

Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.

Info

Publication number
MX2009012990A
MX2009012990A MX2009012990A MX2009012990A MX2009012990A MX 2009012990 A MX2009012990 A MX 2009012990A MX 2009012990 A MX2009012990 A MX 2009012990A MX 2009012990 A MX2009012990 A MX 2009012990A MX 2009012990 A MX2009012990 A MX 2009012990A
Authority
MX
Mexico
Prior art keywords
muscle relaxant
providing
stable
botulinum toxin
basis
Prior art date
Application number
MX2009012990A
Other languages
English (en)
Inventor
Matthias Marx
Karl-Heinz Eisele
Harold V Taylor
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07010912A external-priority patent/EP1997509A1/en
Priority claimed from EP07020025A external-priority patent/EP2048156A1/en
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2009012990A publication Critical patent/MX2009012990A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invenci?n proporciona un proceso para proporcionar un relajante muscular, donde el relajante muscular es una soluci?n reconstituida que comprende un componente neurot?xico de toxina botul?nica libre de prote?nas complejantes, que exhibe al menos una de las siguientes caracter?sticas, de manera m?s preferible todas las caracter?sticas a) a d): a) Estable a temperaturas de almacenamiento superiores a 20?C; b) estable en presencia de preservativos y/o analg?sico; c) resistente contra ciclos de "congelamiento y descongelamiento"; d) estable si se almacena en recipientes de diferente material.
MX2009012990A 2007-06-01 2008-05-28 Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica. MX2009012990A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93262407P 2007-06-01 2007-06-01
EP07010912A EP1997509A1 (en) 2007-06-01 2007-06-01 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US99885807P 2007-10-12 2007-10-12
EP07020025A EP2048156A1 (en) 2007-10-12 2007-10-12 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
PCT/EP2008/004254 WO2008145359A1 (en) 2007-06-01 2008-05-28 Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin

Publications (1)

Publication Number Publication Date
MX2009012990A true MX2009012990A (es) 2010-04-01

Family

ID=40074591

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009012990A MX2009012990A (es) 2007-06-01 2008-05-28 Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.
MX2009012570A MX2009012570A (es) 2007-06-01 2008-05-28 Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009012570A MX2009012570A (es) 2007-06-01 2008-05-28 Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.

Country Status (15)

Country Link
US (2) US20090010965A1 (es)
EP (2) EP2164861A1 (es)
JP (2) JP2010529000A (es)
KR (2) KR20100020971A (es)
CN (2) CN101687018A (es)
AR (2) AR066782A1 (es)
AU (2) AU2008256418A1 (es)
BR (2) BRPI0812322A2 (es)
CA (2) CA2686642A1 (es)
IL (2) IL202129A0 (es)
MX (2) MX2009012990A (es)
RU (1) RU2009149604A (es)
TW (2) TW200914039A (es)
WO (2) WO2008145358A1 (es)
ZA (2) ZA200907875B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
HRP20180739T1 (hr) 2008-12-31 2018-06-29 Revance Therapeutics, Inc. Injekcijske formulacije botulinskog toksina
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
EP2398824B1 (en) * 2009-02-19 2018-12-26 Merz Pharma GmbH & Co. KGaA Means and methods for manufacturing highly pure neurotoxin
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US8663942B2 (en) * 2009-04-27 2014-03-04 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
CA2766521C (en) 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
JP5951490B2 (ja) * 2009-10-21 2016-07-13 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 非複合ボツリヌス神経毒素を精製するための方法およびシステム
BR112013025256B1 (pt) * 2011-03-31 2022-01-18 Medy-Tox Inc Preparação liofilizada farmacêutica
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
JP6798993B2 (ja) 2014-12-23 2020-12-09 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素プレフィルド容器
WO2016124213A1 (en) * 2015-02-03 2016-08-11 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
EP3070539A1 (fr) * 2015-03-17 2016-09-21 Omega SA Montre-bracelet comprenant un cadran muni d'index lumineux
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2020138674A1 (ko) 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
MX2020014330A (es) 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
US20250222081A1 (en) * 2022-04-01 2025-07-10 Chongqing Claruvis Pharmaceutical Co., Ltd. Botulinum toxin protein composition, method for preparing same, and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ATE430797T1 (de) 2005-06-17 2009-05-15 Merz Pharma Gmbh & Co Kgaa Vorrichtung und verfahren zur fermentativen herstellung biologisch wirksamer verbindungen
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
WO2008145359A1 (en) 2008-12-04
ZA200907875B (en) 2010-11-24
AR066782A1 (es) 2009-09-09
EP2164861A1 (en) 2010-03-24
AU2008256418A1 (en) 2008-12-04
JP2010529000A (ja) 2010-08-26
CA2686637A1 (en) 2008-12-04
BRPI0812322A2 (pt) 2014-11-25
CN101720331A (zh) 2010-06-02
MX2009012570A (es) 2010-03-15
CA2686642A1 (en) 2008-12-04
RU2009149604A (ru) 2011-07-20
BRPI0812245A2 (pt) 2014-10-21
US20090028906A1 (en) 2009-01-29
KR20100020972A (ko) 2010-02-23
WO2008145358A1 (en) 2008-12-04
JP2010528999A (ja) 2010-08-26
IL202129A0 (en) 2010-06-16
KR20100020971A (ko) 2010-02-23
TW200902050A (en) 2009-01-16
EP2170375A1 (en) 2010-04-07
ZA200907874B (en) 2011-03-30
CN101687018A (zh) 2010-03-31
TW200914039A (en) 2009-04-01
AU2008256419A1 (en) 2008-12-04
AR066783A1 (es) 2009-09-09
IL202130A0 (en) 2010-06-16
US20090010965A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
MX2009012990A (es) Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.
MY188973A (en) Activin-actrii antagonists and uses for treating anemia
WO2008006422A3 (de) Verwendung von ionischen flüssigkeiten oder lösungen aus metallsalzen in ionischen flüssigkeiten als antistatika für kunststoffe
WO2007028165A8 (en) Stress tolerance in plants
MX357972B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
WO2008143666A3 (en) Crystal structures of neuropilin fragments and neuropilin-antibody complexes
WO2008150867A3 (en) Surfaces having particles and related methods
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
WO2007120651A3 (en) Uses and compositions for treatment of juvenile rheumatoid arthritis
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2008127355A3 (en) Chemorepulsion of cells
ATE554122T1 (de) Polymere mit kondensiertem selenophen
WO2011160016A3 (en) E3 binding pockets and identification and use of e3 ligase inhibitors
MX2011004483A (es) Leucolectinas y sus usos.
WO2006014979A3 (en) Palm fiber-based dietary supplements
WO2007044396A3 (en) Fibronectin polypeptides and methods of use
MX2007001241A (es) Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
WO2006134190A3 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
WO2011056954A8 (en) Haemophilus parasuis polypeptides and methods of use
WO2007085728A3 (fr) Composition comprenant plusieurs toxines botuliques
WO2006135811A3 (en) Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
ZA200705840B (en) Method for treating fungoid growth of rhizoctonia, pythium and phytophthora
MX2012008250A (es) Tratamiento de articulos de parque con conservadores de madera de cobre y/o zinc.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal